Portfolio News

Neuron23 today announced the publication of a manuscript in the Proceedings of the National Academy of Sciences (PNAS), which explores the role of tyrosine kinase 2 (TYK2) inhibition in neuroinflammation, microglia and astrocyte regulation, and modulation of various biomarkers of neuroinflammation in Experimental Autoimmune Encephalomyelitis (EAE), a widely utilized model of multiple sclerosis (MS) and neuroinflammation.

Data from the Phase 1 healthy volunteer study of NEU-411 will be presented at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™), taking place April 1-5 in Vienna.

Financing led by funds managed by Blue Owl Capital; Senior Managing Director Kevin Raidy joins Latigo’s board

LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in Phase 1 trial

Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties

Westlake BioPartners leads $30 million Series A extension, bringing the startup’s total committed capital to $180 million

Data to be featured as oral and poster presentations at American Epilepsy Society 2024 Annual Meeting

Former Horizon Therapeutics chairman & CEO brings 30 years of biopharmaceutical industry experience

Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson’s disease

NEU-411, a brain-penetrant, potent and selective kinase inhibitor, has potential to slow disease progression in up to 30% of people with LRRK2-driven Parkinson’s disease